In 2018, administration of intranasal oxytocin was given for 10 weeks, followed by a combination of intranasal oxytocin and naloxone for 38 weeks in a 13-year-old male with confirmed hypothalamic obesity and hyperphagia following resection of a craniopharyngioma. This evidence concerns the gene OXT and craniopharyngioma.